The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.
The CDC noted that a specific compound or ingredient has yet to be identified as the causative agent in these cases.
Duaklir Pressair is now available for the maintenance treatment of patients with chronic obstructive pulmonary disease.
The FDA has issued a CRL to AstraZaeneca regarding their NDA for PT010, an investigational triple combination therapy for COPD.
Imipenem/relebactam/cilastatin was found to be noninferior to piperacillin/tazobactam in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.
In patients with naïve advanced NSCLC and high PD-LI expression who are treated with pembrolizumab, the use of IV antibiotics may negatively impact progression free survival and overall survival.
The FDA has expanded the indication for Teflaro (ceftaroline fosamil; Allergan) to include treatment of acute bacterial skin and skin structure infections in pediatric patients.
The FDA’s Allergenic Products Advisory Committee voted in favor of the approval of Palforzia (AR101) as a treatment to reduce the incidence and severity of allergic reactions.
The FDA has approved Nucala as an add-on maintenance treatment for patients 6 to 11 years old with severe eosinophilic asthma.
